Discover who we are and our partners global network, as well as learn more about our people.

Learn more about our products and how they provide innovative solutions for patiens' unmet needs.

Discover our capabilities in project design services.

Find information such as website news, press releases and event presentations.

Get in touch with us to set up a meeting or propose your cooperation.

APR TD011
EPIDERMOLYSIS BULLOSA

APR TD011 is a clinical stage drug candidate for the treatment of blisters and wounds in EB patients.

The product thanks to its chemical-physical unique properties is expected to:

Reduce the bioburden allowing both prevention of the infection and ensure an antibioticsparing approach with no bacterial resistance.
Reduce the skin inflammation, which is highly linked with skin cancer and death.
Support a faster healing and allow a reduction risk of scar.

The proposed benefits are expected to be achieved thanks to the peculiar properties of the solution:

Control the bioburden: based on data generated so far it can be postulated that the presence of HClO, a well-known antimicrobial agent, could support a reduction of bioburden, as well as the unique pH/(Oxidation reduction potential) ORP create conditions unfavorable to bacterial growth.
Modulation of metallo-proteases (MMPs): the low pH of the product can decrease the activity of the alkaline-pH-dependent of metalloproteases (MMPs), which are the main triggers for inflammation process. High ORP values may also be involved in the inhibition of MMPs activity.
Modulation of inflammation mediators: molecular analysis shows APR TD011 to be able to modulate several inflammatory pathways.
Tissue regeneration properties: multi-level activity of APR TD011 could lead to an optimal conditions for new cells growth, thus supporting the physiological wound healing process.

TEHCLO® TECHNOLOGY

Tehclo™ is the globally patented nanotechnology platform applied to the production of unique hypochlorous acid solutions that ensures the most consistent quality for best-in-class clinical outcomes.

The nanotechnology applied drives electrolysis using a current several times stronger than other standard electrolysis process, minimizing chloride requirements and producing acid oxidizing solution with >95% hypochlorous acid (HClO) purity and 0% hypochlorite (OCl^-) as well as the lowest pH range (2.5-3.0) and high ORP (>1100 mv).

APR TD011EPIDERMOLYSIS BULLOSA

APR TD011
EPIDERMOLYSIS BULLOSA